Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension

• Status: Unknown status
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pacific Pharmaceuticals
• Treatments: Ramipril

Criteria

Inclusion Criteria:

• mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg)

Exclusion Criteria:

• 180mmHg≤SBP

• If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings

• If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings

• impaired hepatic function

• imapaired renal function

• angioedema

• aortic valvular stenosis or obstrcutive ejection disorder

• primary hyperaldosteronism

• renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis

• severe respiratory disease

• congestive heart failure( New York Association functional class Ⅲ or Ⅳ)

• malignant hypertension

• labile angina pectoris or myocardial infarction in the last 3 months before study entry